HCPCS Level II
Q2049
Injection, doxorubicin hydrochloride, liposomal, imported lipodox, 10 mg
- Category
- Q. Temporary codes
- NDC crosswalk
- None in the loaded CMS ASP file
Codes near Q2049
These sit next to Q2049 in the CMS Level II file. All Q codes
- Q2039Influenza virus vaccine, not otherwise specified
- Q2040Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion
- Q2041Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2042Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2043Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion
- Q2050Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg
- Q2052Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)
- Q2053Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2054Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2055Idecabtagene vicleucel, up to 510 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose